Squarepoint
RDHL

Squarepoint’s Redhill Biopharma RDHL Stock Holding History

Squarepoint’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-438
Closed -$16K – 4504
2023
Q4 		$16K Buy
+438
New +$8.94K ﹤0.01% 3918
2021
Q2 		– Sell
-19
Closed -$136K – 3615
2021
Q1 		$136K Buy
+19
New +$159K ﹤0.01% 2827
2018
Q4 		– Sell
-19
Closed -$169K – 2195
2018
Q3 		$169K Buy
+19
New +$155K ﹤0.01% 1808

Other funds holding RDHL

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's RDHL Position: Q1 2024 in Review

Squarepoint sold out of Redhill Biopharma (RDHL) in Q1 2024, closing a stake of 438 shares — an estimated $16K sold.

Squarepoint first reported a position in RDHL in Q3 2018 and held it in 3 quarters. The position peaked at $169K in Q3 2018. 15 funds tracked by Wall St. Rank hold RDHL as of Q1 2024.

  • Squarepoint reported no remaining Redhill Biopharma position as of Q1 2024 after selling out during the quarter.
  • Squarepoint sold 438 Redhill Biopharma shares in Q1 2024, an estimated $16K.
  • Squarepoint first reported a position in Redhill Biopharma in Q3 2018 and held it in 3 quarters.
  • Squarepoint's Redhill Biopharma position peaked at $169K in Q3 2018.
  • 15 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.